FindTrial
Sign In

Efineptakin alfa

BIOLOGICAL5 trials

Sponsors

Hyunseok Kang, MD, Fred Hutchinson Cancer Center, NeoImmuneTech, Mayo Clinic

Conditions

AIDS-Related Kaposi SarcomaCarcinoma, Non-Small-Cell LungHIV InfectionHigh Grade Astrocytic TumorKaposi SarcomaNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-Small Cell Lung Carcinoma

Phase 1

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
TerminatedNCT04588038
Hyunseok Kang, MDRecurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma +3
Start: 2021-03-12End: 2025-02-03Updated: 2025-02-14
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
TerminatedNCT04893018
Fred Hutchinson Cancer CenterAIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
Start: 2022-05-23End: 2023-12-15Updated: 2024-06-27
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
CompletedNCT05075603
NeoImmuneTechRecurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +2
Start: 2021-08-06End: 2025-03-12Updated: 2025-10-23

Phase 2

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Active, not recruitingNCT04984811
NeoImmuneTechCarcinoma, Non-Small-Cell Lung, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer +2
Start: 2021-11-03End: 2025-03-31Target: 83Updated: 2024-03-05
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
RecruitingNCT05465954
Mayo ClinicHigh Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Start: 2023-01-24End: 2028-10-15Target: 54Updated: 2026-01-12

Related Papers

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma
Blood2025-11-03
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Journal for ImmunoTherapy of Cancer2025-02-015 citations
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
Journal of Clinical Oncology2023-06-013 citations
679 NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: a clinical trial in progress
Regular and Young Investigator Award Abstracts2022-11-01
Expansion of CAR-T Cells in Vivo With Long-Acting Interleukin-7 Analog
Oncology Times2022-08-17
Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.
Journal of Clinical Oncology2022-06-01